Sempra's Oncor files $560M annual rate increase settlement with Texas PUCT; ROE set at 9.75%

SEMPRA

Oncor stipulation seeks annual revenue requirement of ~$6.975B, an 8.8% increase over present revenues.
Aggregate annualized revenue increase of ~$560M; authorized ROE rises to 9.75% (from 9.70%) and debt cost to 4.94%.
Capital structure revised to 56.5% debt / 43.5% equity; self-insurance reserve accrual increased to $200M/yr from $122M.
Final PUCT order expected H1 2026; new rates backdated to Jan 1, 2026 if approved as filed.
Sempra expects positive impacts to Oncor's future earnings, cash flow, and credit metrics.

item 7.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.